Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 23, 2021

BioAge begins trial of oral inhibitor to treat Covid-19 patients

BioAge Labs has initiated a Phase II clinical trial of a potent oral inhibitor of prostaglandin D2 (PGD2) DP1 signalling, BGE-175, for treating Covid-19 patients aged 60 years and above. 

BioAge Labs has initiated a Phase II clinical trial of a potent oral inhibitor of prostaglandin D2 (PGD2) DP1 signalling, BGE-175, for treating Covid-19 patients aged 60 years and above.

DP1 signalling is linked to high chances of infection and an increased risk of mortality from the infectious disease.

In various Phase I–III clinical trials for allergic rhinitis carried out by Shionogi & Co, BGE-175 showed to be safe and well-tolerated in more than 2,400 study subjects.

The randomised, placebo-controlled, parallel-group, multi-centre, double-blind Phase II study will have elderly subjects hospitalised for Covid-19 without respiratory failure.

It will enrol a total of 132 subjects in the US, Argentina, and Brazil. They will be given daily doses of BGE-175 or placebo (66 in each group) for up to 14 days.

Patients will receive the study medication orally while patients unable to swallow will receive it through a nasogastric tube.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The percentage of patients who die or develop respiratory failure within 28 days of receiving the first dose of BGE-175 will form the trial’s primary endpoint.

Viral load, clinical improvement or worsening, incidence and duration of supplementary oxygen or ventilation, time to discharge or rehospitalisation ICU admission, in 57 days after the first dose, will be the secondary endpoints.

Furthermore, PGD2 DP1 signalling activity and the levels of inflammatory markers will be studied.

BioAge CEO Kristen Fortney said: “By reversing age-related dysregulation of critical immune mechanisms, BGE-175 could allow older patients to more effectively fight off Covid-19.

“Our strongly encouraging preclinical data show that BGE-175 almost completely protects older mice against lethality from infection with SARS-CoV-2, the virus that causes Covid-19.

“In addition, BGE-175 dramatically decreases viral load in lung tissue, which is correlated with both disease severity and transmission of the virus.”

The company anticipates top-line results this year.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU